Physician profile
Michael Alan Levine
NPI 1811033962
$128,113.77
in general payments reported to CMS, 2019-2025
20 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $4,116 · 2021: $7,570 · 2022: $11K · 2023: $26K · 2024: $29K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $55K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,670 · Honoraria: $5,454 · Food and Beverage: $407 · Travel and Lodging: $75.25 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,461.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,670.00 |
| Honoraria | $5,454.00 |
| Food and Beverage | $407.02 |
| Travel and Lodging | $75.25 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| American Regent | $30,119.05 | 2019-2023 | Injectafer |
| Shire North American Group INC | $16,228.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13,356.30 | 2024-2025 | |
| Immedica Pharma US, INC. | $10,150.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,290.00 | 2021-2025 | Natpara (Parathyroid Hormone) |
| Kyowa Kirin, INC. | $8,809.62 | 2023 | |
| Pfizer INC. | $8,500.00 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $5,642.00 | 2025 | Monoferric |
| Ascendis Pharma Endocrinology INC | $5,330.00 | 2022 | |
| Biomarin Pharmaceutical INC. | $5,102.78 | 2019 | |
| Merck Sharp & Dohme LLC | $4,800.00 | 2022 | |
| Csl Behring | $4,200.00 | 2024 | Hemgenix |
| Day One Biopharmaceuticals | $3,500.00 | 2024 | Ojemda |
| Mirum Pharmaceuticals, INC. | $1,400.00 | 2024-2025 | |
| Novo Nordisk Health Care Ag | $1,000.00 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin Co., LTD | $475.00 | 2022 | |
| Next Science LLC | $154.65 | 2023 | Surgx, Blastx, Xperience |
| Corcept Therapeutics | $33.50 | 2025 | Korlym |
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.